v3.23.2

Condensed Consolidated Statements Of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses/ (income):
General and administrative	$ 53,651	$ 110,830	$ 252,462	$ 309,527
Research and development	46,672	17,030	78,332	43,389
Common stock issued for services (see Note 6)			3,858,793
Gain on settlement of accounts payable				(150,000)
Gain on settlement of related party payable				(375,000)
Total operating expenses/ (income)	100,323	127,860	4,189,587	(172,084)
Loss/ (income) from operations	(100,323)	(127,860)	(4,189,587)	172,084
Other income/(expense):
Accretion of debt discount		(589,868)	(180,333)	(870,421)
Interest expense	(4,840)	(2,264)	(23,031)	(41,265)
Gain on derivative liability		73,569	8,744	112,538
Total other expenses	(4,840)	(518,563)	(194,620)	(799,148)
Income tax provision
Net (Loss) Income	$ (105,163)	$ (646,423)	$ (4,384,207)	$ (627,064)
Basic loss per share attributable to common shareholders (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
Diluted net loss per share attributable to common shareholders (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
Basic weighted average common shares outstanding (in Shares)	771,811,360	127,155,100	513,931,733	88,323,702

Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-3

Rasna Therapeutics Inc. 10-Q